OTC · Health care

Aibotics, Inc. (AIBT)

Aibotics, Inc. brought in $0 of revenue over the twelve months to June 30, 2026, down 100.0% from a year earlier. It posted a net loss of $2.1M. At June 30, 2026 it held $233.4K in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 19, 2026.

Watch AIBT in 60 seconds

Price

$0.00

+11.11% on the day · September 25, 2026

52-week range $0.00 to $0.01

Market cap

$850.2K

Revenue (last 12 months)

-100.0% year on year

What Aibotics, Inc. does

Aibotics, Inc. is registered with the SEC under industry code SIC 2833 (Medicinal Chemicals & Botanical Products). Its shares trade on OTC under the ticker AIBT.

Revenue and profit by year

Revenue

Net income

Fiscal years as reported in annual reports. Amounts in USD.

Key figures

Fiscal year	Revenue	Operating income	Net income	Diluted EPS	Free cash flow
2025	$2.2K	-$1.8M	-$2.2M	n/a	n/a
2024	$0	-$1.6M	-$1.8M	n/a	n/a
2023	n/a	-$616.7K	-$1.2M	n/a	n/a
2022	n/a	-$1.7M	-$2.6M	n/a	-$656.6K
2021	n/a	-$5M	-$5.1M	n/a	-$238.2K
2020	n/a	-$14.2K	-$16K	n/a	-$14.3K

Full financial statements: income, balance sheet and cash flow

Next report expected around November 18, 2026.

Estimated from its filing rhythm: 52 weeks after its report of November 19, 2025. Not a date the company has announced. See the report calendar

Where AIBT ranks in Health care

Revenue$2.2K

#742 of 742 in Health care · Bottom 1%

Latest fiscal year of every company in the sector with the figure reported. Revenue is ranked among companies reporting in US dollars; growth and margins among companies with at least 10 million of revenue. Health care

Latest SEC filings

What Aibotics, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.

August 19, 2026
Quarterly report 10-Q · period to June 30, 2026Net loss of $537K.
August 14, 2026
Late quarterly report notice NT 10-Q
June 9, 2026
Quarterly report 10-Q · period to March 31, 2026Net loss of $418.1K.
May 15, 2026
Late quarterly report notice NT 10-Q
April 15, 2026
Annual report 10-K · period to December 31, 2025Revenue was $2.2K; net loss of $2.2M.
March 31, 2026
Late annual report notice NT 10-K
January 28, 2026
Employee stock plan registration S-8
November 19, 2025
Quarterly report 10-Q · period to September 30, 2025Net loss of $529.9K.
November 14, 2025
Late quarterly report notice NT 10-Q
August 19, 2025
Quarterly report 10-Q · period to June 30, 2025Net loss of $486.1K.

Recent insider filings (Forms 3, 4 and 144): 6, the latest on July 28, 2025. Insider transactions on SEC

All filings on SEC EDGAR

Questions about AIBT

What does Aibotics, Inc. do?

Aibotics, Inc. is registered with the SEC under industry code SIC 2833 (Medicinal Chemicals & Botanical Products). Its shares trade on OTC under the ticker AIBT.

Is Aibotics, Inc. profitable?

No. Over the twelve months to June 30, 2026 it reported a net loss of $2.1M.

How much revenue does Aibotics, Inc. make?

Over the twelve months to June 30, 2026 Aibotics, Inc. reported revenue of $0. That is 100.0% less than a year earlier.

When did Aibotics, Inc. last report?

Its most recent periodic report is the quarterly report (10-Q) filed on August 19, 2026. It covers the period to June 30, 2026.

Similar companies

CURLF

Curaleaf Holdings, Inc.

TRLV

Trulieve Cannabis Corp.

SNDL

SNDL Inc.

USNA

Usana Health Sciences Inc

Compare AIBT with

Compare AIBT with any company

Follow AIBT

Get an email when Aibotics, Inc. files with the SEC: results, executive changes, material agreements and annual reports.

Follow AIBT: get an email when it files

Where the numbers come from

Financial figures are the values Aibotics, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.

Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.